This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Martinez-Valle, F Articles by Vilardell-Tarres, M Search for Related Content PubMed PubMed Citation Articles by Martinez-Valle, F Articles by Vilardell-Tarres, M Social Bookmarking                         What's this?

DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

E Balada

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

J Ordi-Ros

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

S Bujan-Rivas

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

A Sellas-Fernandez

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

M Vilardell-Tarres

Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research Institute, Hospital Vall d’Hebron, Barcelona, Spain

The main objective of this study is to determine the relationship between the activity of DNase1 and the clinical and immunological features in patients with systemic lupus erythematosus (SLE). A total of 66 patients (8 men and 58 women) diagnosed with SLE according to the American College of Rheumatology (ACR) SLE classification criteria were included in the study. Sixty-two sera from healthy blood donors were also included as controls. Epidemiological, clinical, immunological and therapeutical features for each patient were obtained. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). DNase1 activity was determined by using a radial enzyme diffusion method. Statistical analysis was performed using SPSS 12.0 software, with significant P value <0.05. Dnase1 activity was lower in patients with SLE than in the control group: 13.69 ± 8.52 µg/mL vs 24.75 ± 12.32 µg/mL, respectively (P < 0.005). No statistical relationship was found between DNase1 activity and disease evolution time, hypertension, presence of absolute or relative proteinuria, SLEDAI, new clinical manifestations, anti-Ro antibodies, anti-La antibodies, anti-RNP antibodies, anti-DNA antibodies, anti-cardiolipin antibodies, lupus anticoagulant, or with the treatment pattern received by the patients. Although important differences in DNase1 activity were found between patients with or without anti-Sm antibodies, they did not reach statistical significance. DNase1 activity was significantly lower in patients with SLE. Nevertheless, we did not find further relationships with any other of the epidemiological, clinical, immunological or therapeutical variables considered.

Key Words: auto-antibodies • disease activity • DNase1 activity • systemic lupus erythematosus

Lupus, Vol. 18, No. 5, 418-423 (2009)
DOI: 10.1177/0961203308098189


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?